BPA for haegarda

Ended Awarded Last action

Contract number
36E79721A0024
Awardee
Awarding agency
Task orders
1 $87,957 obligated

Award facts

Opportunity
  • VA797P12Q0002 Solicitation number
Combined order value
$87,957 Current and potential, with all options
Last date to order 100% complete
IDV ceiling 1% used
$17,500,000.00
Award type
Single award
Who can order
Only the awarding agency
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
Pricing
Firm Fixed Price

Award details come from SAM.gov/FPDS.

About this IDV

CSL Behring L.L.C., a global biotherapeutics company headquartered in King of Prussia, Pennsylvania, was awarded a single-award Blanket Purchase Agreement by the National Acquisition Center on September 30, 2021, for the procurement of HAEGARDA, a C1 inhibitor medication used to treat hereditary angioedema. The BPA carries a ceiling value of $17.5 million and extends through September 29, 2026, with performance conducted at CSL Behring's manufacturing and distribution facility in King of Prussia, Pennsylvania. As a civilian procurement for the Department of Veterans Affairs, this agreement utilizes firm fixed pricing with no set-aside designations applied, reflecting CSL Behring's status as a large enterprise contractor. The BPA serves as a primary vehicle for coordinated supply of HAEGARDA across the Veterans Health Administration system, enabling efficient procurement through pre-negotiated pricing and terms for VA medical facilities nationwide.

Under this BPA, the Veterans Affairs Greater Los Angeles Healthcare System Pharmacy issued a task order call on February 21, 2022, valued at approximately $87,957 for HAEGARDA drug procurement, with completion scheduled for March 21, 2022. This call exemplifies the operational structure wherein individual Veterans Integrated Service Networks execute delivery orders against the master BPA for their respective pharmacy needs. CSL Behring also supplies related specialty pharmaceutical products including Privigen, Hizentra, and Kcentra through the broader Federal Supply Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB), which carries a ceiling value of approximately $201.5 million through September 2026. The coordinated use of these IDVs enables the Veterans Health Administration to maintain consistent access to critical hereditary angioedema treatments and related hematology therapies across multiple regional service networks while leveraging pre-established pricing arrangements.

Task orders

Task order Ordering agency Obligated Awarded
Haegarda drug purchase for VA GLA HCS pharmacy 36C26222N0328 Veterans Integrated Service Network 22 (VHA) $87,957

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00009 · 2026 public law pricing updates. $0
Exercise an Option P00008 · This modification is issued to exercise option year 4 on BPA 36E79721A0024. $0
Supplemental Agreement for work within scope P00007 · 2025 public law pricing updates $0
Exercise an Option P00006 · This modification is issued to exercise option year 3 on BPA 36E79721A0024. $0
Supplemental Agreement for work within scope P00005 · 2024 public law pricing updates $0
Exercise an Option P00004 · This modification is issued to exercise option year 2 on BPA 36E79721A0024. The period of performance is 09/30/2023 - 09/29/2024. $0
Supplemental Agreement for work within scope P00003 · 2023 public law pricing updates $0
Exercise an Option P00002 · Exercise option year 1 on BPA 36E79721A0024 $0
Supplemental Agreement for work within scope P00001 · 2022 public law pricing updates $0
Original award $0

Quick answers

Who was awarded contract 36E79721A0024?

36E79721A0024 was awarded to CSL Behring L.L.C. by National Acquisition Center (Headquarters) on September 30, 2021.

How much is contract 36E79721A0024 worth?

Orders under 36E79721A0024 have obligated $87,957. 36E79721A0024's own ceiling is $17,500,000.

How many orders have been placed under contract 36E79721A0024?

1 order has been placed under 36E79721A0024, the latest on February 21, 2022.

Who can order from contract 36E79721A0024?

36E79721A0024 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.

Is contract 36E79721A0024 under another contract?

Yes. 36E79721A0024 is a blanket purchase agreement under 36F79721D0249, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).

Was contract 36E79721A0024 competed?

The extent of competition for 36E79721A0024 was full and open competition. The government received 1 offer.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV